Carrick Therapeutics’ Phase 2 Clinical Trial of Samuraciclib combined with Fulvestrant has dosed its first patient. The study targets patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer. Samuraciclib is a selective oral, first-in-class inhibitor of CDK7. It is involved in the regulation of cancer-causing genes, promotion of uncontrolled cell cycle progression, and increase in resistance to anti-hormone therapy. The comb previously receives the Fast Track Designation from the U.S. FDA.